Biological markers for treatment-resistant psychiatric disorders
Part of Brain & nervous system, Mental health clinical trials.
This study looks for biological markers in the blood or spinal fluid that might predict how well a new psychiatric treatment will work. If you have a psychiatric condition that hasn't improved with previous treatments, this research could help find better ways to match treatments to individuals in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a psychiatric disorder diagnosed according to standard criteria (DSM-5).
- Your condition has not improved with previous treatments (treatment-resistant).
- You are about to start a new treatment for your condition.
- You are willing to sign a consent form and are covered by social security.
- You do not have a major neurocognitive disorder (like dementia), are not pregnant or breastfeeding, and are not deprived of liberty by court order.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “biomarkers,” or blood measures, in people with schizophrenia who respond to clozapine. It may help researchers understand who benefits from clozapine and why, by linking test results to symptom changes.
This study looks at how certain molecules (called non-coding RNAs) relate to mental health conditions like bipolar disorder, depression, anxiety, OCD, or schizophrenia. By comparing patients who haven't been on psychiatric medication for at least 6 months with healthy volunteers, researchers hope to find better ways to diagnose and understand these conditions.
This trial tests a new medical device that uses a blood test to help doctors accurately diagnose bipolar disorder in people who were thought to have major depression. It aims to see if the device can tell the difference and improve treatment choices.
This study looks at neurofilament light (a brain/nerve injury marker) and how it relates to thinking and memory problems in people with certain psychiatric conditions. It may help researchers understand brain changes and cognitive impairment, which could guide better diagnosis in the future.
This study uses a blood test (biomarker) to help pick the antidepressant that might work best for you. It compares two treatments—standard antidepressants and ketamine—in people with major depression who haven't gotten enough relief from one prior treatment.
This study builds a database of brain-signal measurements to help find “biomarkers” that may point to schizophrenia or related mental illnesses. Depending on whether you have a mental health diagnosis or you’re healthy, the study will collect information and brain data to compare groups.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.